Trial · NCT06680206
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
NCT06680206, Completed, Pfizer; results first posted 2026-01-22
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey. Trials, record NCT06680206. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06680206
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
- NCT number
- NCT06680206
- Status
- Completed
- Enrollment
- 1,395 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Migraine
- Interventions
- Rimegepant, Triptans
- First posted
- 2024-11-08
- Last updated
- 2026-01-22
- Results first posted
- 2026-01-22
Source ClinicalTrials.gov
Registered outcomes53
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants according to migraine medication type: 1) as prescription drug only, 2) as OTC only or 3) as both prescription drug and OTC based on the use of migraine medication classes is reported in this outcome measure. Analysis was performed using inverse probability treatment weighting (IPTW) method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Migraine Treatment Type (Acute or Prevention) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants according to migraine treatment type: 1) acute use only, 2) prevention use only, or 3) both acute and prevention use based on the use of migraine medication classes is reported in this outcome measure. Acute treatments included: triptans, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment; preventive treatment included: anticonvulsants, beta blocker, antidepressant, calcitonin gene-related peptide antibodies monoclonal antibodies (CGRP mAb), botox, and gepant \[prevention treatment including Nurtec\]). Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Total Number of Acute Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Total number of distinct acute migraine agent drug classes used by participants is reported as mean in this outcome measure. Acute migraine agents included: triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Number of Acute Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants categorized by the number of distinct acute migraine agent drug classes used is reported in this outcome measure. Categories included 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Total Number of Prevention Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Preventive migraine agents included: anticonvulsants, beta blocker, antidepressant, CGRP mAb, botox, and gepant \[prevention treatment including Nurtec\]. Total number of distinct preventive migraine agent drug classes used by participants is reported as mean in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants categorized by the number of distinct prescription preventive migraine agent drug classes used reported in this outcome measure. Categories included use of 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Current Migraine Treatments | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants according to current migraine treatments on drug classes including: Nurtec (rimegepant) only, acute agents, triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment (aspirin lysine/metoclopramide hydrochloride monohydrate or indometacin/caffeine/prochlorperazine), prevention agents (anticonvulsants, beta-blocker, antidepressant, CGRP mAb, botox, and gepant) are reported in this outcome measure. One participant could receive more than one migraine treatment. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Treatment Satisfaction of Migraine Drug Class | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Number of participants according to treatment satisfaction for the migraine drug classes including: acute agents, NSAIDs, opioids, barbiturates, ergots, gepants (acute), ditans, combination analgesics, other, prevention agents, anticonvulsants, beta blockers, antidepressants, CGRPs mAb, botox, and gepant reported in this outcome measure. Treatment satisfaction for each of the migraine drug class was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
| Primary | Number of Participants According to Current Migraine Treatments on OTC Class | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Participants were categorized based on current use of OTC migraine treatments, including analgesics (acetaminophen only), analgesics (combination), NSAIDs, and other OTCs. |
| Primary | Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study | Number of participants according to treatment satisfaction for analgesics (acetaminophen only) is reported in this outcome measure. Treatment satisfaction was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates. |
1 to 10 of 53Source ClinicalTrials.gov
See all 53 registered outcomesOutcomes53
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Migraine Treatment Type (Acute or Prevention) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Total Number of Acute Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. | Drug classes per participant | MEAN |
| PRIMARY | Number of Participants According to Number of Acute Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Total Number of Prevention Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. The analysis was performed on all participants reported under Overall Number of Participants Analyzed. | Drug classes per participant | MEAN |
| PRIMARY | Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. The analysis was performed on all participants reported under Overall Number of Participants Analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Current Migraine Treatments | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Treatment Satisfaction of Migraine Drug Class | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Current Migraine Treatments on OTC Class | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Analysis was performed on all participants reported under Overall Number of Participants Analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only) | At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study | Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 53Source ClinicalTrials.gov
See all 53 outcomesResults by group468
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Rimegepant | Prescription Drug only | 74 | Participants | |
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Triptans | Prescription Drug only | 682 | Participants | |
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Rimegepant | Prescription drug and OTC | 61 | Participants | |
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Triptans | Prescription drug and OTC | 578 | Participants | |
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Rimegepant | OTC only | 0 | Participants | |
| Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | Triptans | OTC only | 0 | Participants | |
| Number of Participants According to Migraine Treatment Type (Acute or Prevention) | Rimegepant | Acute use only | 0 | Participants | |
| Number of Participants According to Migraine Treatment Type (Acute or Prevention) | Triptans | Acute use only | 837 | Participants | |
| Number of Participants According to Migraine Treatment Type (Acute or Prevention) | Rimegepant | Prevention use only | 0 | Participants | |
| Number of Participants According to Migraine Treatment Type (Acute or Prevention) | Triptans | Prevention use only | 0 | Participants |
1 to 10 of 468Source ClinicalTrials.gov
See all 468 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rimegepant | 137 | |
| Overall Study | STARTED | Triptans | 1,258 | |
| Overall Study | Inverse Probability Treatment Weighting (IPTW) Adjustment | Rimegepant | 135 | |
| Overall Study | Inverse Probability Treatment Weighting (IPTW) Adjustment | Triptans | 1,260 | |
| Overall Study | Sensitivity Analysis | Rimegepant | 105 | |
| Overall Study | Sensitivity Analysis | Triptans | 1,258 | |
| Overall Study | Sensitivity Analysis IPTW Adjustment | Rimegepant | 103 | |
| Overall Study | Sensitivity Analysis IPTW Adjustment | Triptans | 1,257 | |
| Overall Study | COMPLETED | Rimegepant | 137 | |
| Overall Study | COMPLETED | Triptans | 1,258 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rimegepant | 0 | 0 |
| Total, all-cause mortality | Triptans | 0 | 0 |
| Total, other adverse events | Rimegepant | 0 | 0 |
| Total, other adverse events | Triptans | 0 | 0 |
| Total, serious adverse events | Rimegepant | 0 | 0 |
| Total, serious adverse events | Triptans | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons12
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis | Trial comparisons |
1 to 10 of 12
See all 12 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06680206
GET https://conductscience.org/api/trials/v1/NCT06680206/registered?page=2